REG - Ergomed plc - Notice of Interim Results

ErgomedAnnouncement

20/08/2020 07:00

RNS Number : 6329W
  
Ergomed plc
  
20 August 2020
  
 

 
PRESS RELEASE
 
Notice of Interim Results
 
 
Guildford, UK - 20 August 2020: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialized services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2020 on 22 September 2020.
 
Miroslav Reljanović, Executive Chairman and Richard Barfield, Chief Financial Officer will host a virtual presentation and conference call for analysts at 9am BST on the day of the results. 
 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart 


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognized specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NORBLGDIRUBDGGC